title: Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content.
abstract: OBJECTIVE
  The ability of a prolonged antiretroviral treatment interruption to reverse mitochondrial toxicity was evaluated in a sub-study of TIBET, a prospective trial examining antiretroviral treatment interruption guided by CD4+ cell count.
  
  
  METHODS
  The study population was composed of patients from the TIBET study who had been followed for > or =96 weeks and whose peripheral blood mononuclear cells (PBMCs) had been collected at baseline and throughout the study period. Of the 201 patients included in the TIBET study, 38 were selected for the mitochondrial sub-study; 18 patients discontinued antiretroviral therapy for > or =96 weeks and 20 maintained therapy. Mitochondrial DNA (mtDNA) and RNA (mtRNA) were measured in PBMCs using real-time polymerase chain reaction, and mitochondrial function relative to mitochondrial content was assessed using the cytochrome c oxidase and citrate synthase ratio (COX/CS).
  
  
  RESULTS
  Whereas mtDNA content showed a similar progressive decrease throughout the study period in both arms, the mtRNA amount remained stable in both groups and the COX/CS ratio improved significantly in patients who interrupted therapy
  
  
  CONCLUSIONS
  Mitochondrial function improved during a prolonged antiretroviral treatment interruption despite a decrease in mtDNA levels in PBMCs, probably because of the existence of a mitochondrial transcriptional and translational upregulation mechanism or the reversion of mitochondrial toxicity by a mechanism that is independent of DNA polymerase gamma. The reduction in virus-related mitochondrial damage should be considered another relevant benefit of antiretroviral therapy.
authors.affiliation: Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Negredo
authors.forename: Joan
authors.initials: J
authors.lastname: Romeu
authors.forename: Benjamí
authors.initials: B
authors.lastname: Rodríguez-Santiago
authors.forename: Oscar
authors.initials: O
authors.lastname: Miró
authors.forename: Glòria
authors.initials: G
authors.lastname: Garrabou
authors.forename: Jordi
authors.initials: J
authors.lastname: Puig
authors.forename: Núria
authors.initials: N
authors.lastname: Pérez-Alvarez
authors.forename: Constanza
authors.initials: C
authors.lastname: Moren
authors.forename: Lidia
authors.initials: L
authors.lastname: Ruiz
authors.forename: Rocio
authors.initials: R
authors.lastname: Bellido
authors.forename: Cristina
authors.initials: C
authors.lastname: Miranda
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002950:Citrate (si)-Synthase / Q000235:genetics / Q000378:metabolism; D004272:DNA, Mitochondrial / Q000032:analysis / Q000235:genetics*; D003576:Electron Transport Complex IV / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000201:enzymology; D008297:Male; D008928:Mitochondria / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D011446:Prospective Studies; D028761:Withholding Treatment
chemical_list: D044966:Anti-Retroviral Agents; D004272:DNA, Mitochondrial; D003576:Electron Transport Complex IV; D002950:Citrate (si)-Synthase